The overexpression of ARHGEF2 is sufficient to increase ERK1/2 phosphorylation raising the possibility that the oncogenic potential of ARHGEF2 is partially mediated through its capacity to activate the MAPK pathway in pancreatic cancer. The gene discussed is MAPK3; the disease is familial pancreatic carcinoma.